Overlapping Extremes: An Analysis of Avelumab Maintenance and Pembrolizumab in Advanced Urothelial Carcinoma.

ABSTRACT:

Introduction

Avelumab and pembrolizumab are approved immune checkpoint inhibitors (ICIs) for advanced urothelial carcinoma (UC) that are used as maintenance and salvage therapies, respectively. The aim of this study was to highlight patterns of extreme response and support the development of biomarker-driven strategies to optimise patient selection and treatment sequencing.

Methods

This was a prospective study that included 79 patients with advanced UC treated with avelumab (n = 32) or pembrolizumab (n = 47) following platinum-based chemotherapy. Outcomes included objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS).

Results

Avelumab was associated with a DCR of 84.4% and a complete response (CR) rate of

SUBMITTER: Catalano M 

PROVIDER: S-EPMC12647452 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature